Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies

Roche announced positive data from the NIH-sponsored OUtMATCH study, comparing Xolair and oral immunotherapy (OIT) for food allergies. The head-to-head trial showed Xolair superior, with fewer adverse events leading to study discontinuation compared to OIT. Xolair enabled a higher percentage of patients to tolerate significant amounts of allergenic foods. Preliminary Stage 3 data indicates potential for introducing allergenic foods after Xolair treatment, though success varied by allergen. Higher success rates were observed for milk, egg, and wheat compared to peanuts and tree nuts. Adverse events, including anaphylaxis, were noted in the Stage 3 dietary introduction phase. The study highlights Xolair's efficacy as a treatment option for food allergies. Xolair is FDA-approved for reducing allergic reactions in patients with food allergies. The findings were presented at the 2025 AAAAI Annual Meeting. The study underscores the need for further research into food allergy treatments.